The WuXi Biologics, Eli Lilly and Alexandria Real Estate Equities-backed cancer therapy developer is targeting $74.7m in its IPO.

Having confidentially filed in late April, Karuna Therapeutics has publicly applied for an initial public offering that would raise $75m and provide exits to Nan Fung and PureTech Health.

The health testing kit developer has received $14.5m in series C round funding from investors including corporate backer Xiamen C&D.

The medicine discovery technology developer landed $15.9m in a round led by UCHealth that included Presbyterian Healthcare Services, Children’s Hospital Colorado and UnityPoint Health.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Facit’s seed-stage investments have helped its portfolio garner a total of $750m in follow-on commitments and commercial partnerships, a milestone attesting to its role in oncology-focused biotech innovation in Ontario.

M Ventures has backed the ETH Zurich spinout, which has devised a digital biomarker-driven medical device for diagnosing brain conditions such as Alzheimer's disease.

The immunotherapy technology developer has set a $230m target for an initial public offering that would offer exits to LabCorp, Illumina, Celgene and BD Biosciences.

Novo, GlaxoSmithKline, Pfizer, AbbVie, ShangPharma and Schrödinger are all in line for exits following the small-molecule drug developer's decision to file for an $86.3m initial public offering.

The healthcare data integration platform received $12.7m in a round featuring corporate joint venture Echo Health Ventures, which took part as an existing investor.